Artia Global Partners LP Takes Position in Kodiak Sciences Inc. $KOD

Posted by George Bondi on Jun 18th, 2026

Artia Global Partners LP bought a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 17,019 shares of the company’s stock, valued at approximately $476,000.

Other large investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after purchasing an additional 916 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $72,000. Strs Ohio purchased a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $87,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $119,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a report on Friday, March 27th. Chardan Capital upgraded shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $14.00 to $61.00 in a report on Monday, May 11th. UBS Group lifted their target price on shares of Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 27th. Finally, Wall Street Zen upgraded shares of Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.14.

Check Out Our Latest Stock Analysis on Kodiak Sciences

Kodiak Sciences Stock Up 8.4%

Shares of NASDAQ KOD opened at $35.71 on Thursday. Kodiak Sciences Inc. has a twelve month low of $3.43 and a twelve month high of $47.84. The firm has a market cap of $2.23 billion, a P/E ratio of -8.56 and a beta of 2.21. The company has a 50 day moving average of $38.95 and a 200 day moving average of $30.89.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.01). As a group, equities analysts expect that Kodiak Sciences Inc. will post -3.89 earnings per share for the current fiscal year.

About Kodiak Sciences

(Free Report)

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.